Skip to content
10-Q

Quarterly Report

ZYVERSA THERAPEUTICS, INC. ZVSA

0001493152-26-022759

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 8.1M sh
Shares Diluted Q1 2026 · Mar 31, 2026 8.1M sh
Shares Diluted Q1 2026 · Mar 31, 2025 3.11M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$799.12K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.77M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$14.12M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$12.39M
Stockholders Equity Q1 2026 · Mar 31, 2025 $8.13M
Stockholders Equity Q1 2026 · Dec 31, 2024 $8.52M
Current Liabilities Q1 2026 · Mar 31, 2026 $14.87M
Current Liabilities Q1 2026 · Dec 31, 2025 $12.85M
Total Liabilities Q1 2026 · Mar 31, 2026 $14.87M
Total Liabilities Q1 2026 · Dec 31, 2025 $12.85M
Current Assets Q1 2026 · Mar 31, 2026 $742.22K
Current Assets Q1 2026 · Dec 31, 2025 $463.45K
Total Assets Q1 2026 · Mar 31, 2026 $742.22K
Total Assets Q1 2026 · Dec 31, 2025 $463.45K
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.22
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.73
Eps Basic Q1 2026 · Mar 31, 2026 −$0.22
Eps Basic Q1 2026 · Mar 31, 2025 −$0.73
Sga Expense Q1 2026 · Mar 31, 2026 $1.25M
Sga Expense Q1 2026 · Mar 31, 2025 $1.89M
Rd Expense Q1 2026 · Mar 31, 2026 $57.62K
Rd Expense Q1 2026 · Mar 31, 2025 $258.88K
Net Income Q1 2026 · Mar 31, 2026 −$1.79M
Net Income Q1 2026 · Mar 31, 2025 −$2.26M
Operating Income Q1 2026 · Mar 31, 2026 −$1.3M
Operating Income Q1 2026 · Mar 31, 2025 −$2.14M